Intense Management of Diabetes Mellitus: Role of Glucose Control and Antiplatelet Agents

Journal of Clinical Pharmacology

Volumn 44, Issue 4, 2004, Pages 414-422

  Mudaliar, Sunder ^a,b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b VA SAN DIEGO HEALTHCARE SYSTEM   (United States)

Author keywords

Antiplatelet agents; Glucose control; Intensive treatment; Type 2 diabetes

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ACARBOSE; ACETYLSALICYLIC ACID; ALPHA GLUCOSIDASE INHIBITOR; ANTIDIABETIC AGENT; ANTITHROMBOCYTIC AGENT; BEZAFIBRATE; CLOPIDOGREL; GLIBENCLAMIDE PLUS METFORMIN; GLIPIZIDE; GLIPIZIDE PLUS METFORMIN; GLUCOSE; INSULIN; INSULIN SENSITIZING AGENT; METFORMIN; METFORMIN PLUS ROSIGLITAZONE; MIGLITOL; NATEGLINIDE; PIOGLITAZONE; REPAGLINIDE; ROSIGLITAZONE; SULFONYLUREA DERIVATIVE; TICLOPIDINE;

BLEEDING; BLINDNESS; BLOOD PRESSURE; CARDIOVASCULAR RISK; CONFERENCE PAPER; DIABETES MELLITUS; DIABETIC NEPHROPATHY; DIABETIC NEUROPATHY; DIABETIC RETINOPATHY; DIALYSIS; DRUG HYPERSENSITIVITY; DYSPEPSIA; FLATULENCE; GASTROINTESTINAL SYMPTOM; GLUCOSE BLOOD LEVEL; GLUCOSE HOMEOSTASIS; HUMAN; KIDNEY FAILURE; LACTIC ACIDOSIS; LIPID BLOOD LEVEL; MICROANGIOPATHY; MORBIDITY; MORTALITY; NAUSEA; NEUROPATHIC PAIN; NEUTROPENIA; NON INSULIN DEPENDENT DIABETES MELLITUS; POPULATION RISK; RETINA HEMORRHAGE; RISK FACTOR; SIDE EFFECT; STROKE; THROMBOCYTE FUNCTION; TREATMENT PLANNING; TROPHIC ULCER; VITREOUS HEMORRHAGE; VOMITING;

ASPIRIN; BLOOD GLUCOSE; CARDIOVASCULAR DISEASES; DIABETES MELLITUS, TYPE 2; DRUG THERAPY, COMBINATION; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPOGLYCEMIC AGENTS; PLATELET AGGREGATION INHIBITORS; PRACTICE GUIDELINES; RANDOMIZED CONTROLLED TRIALS;

EID: 1642273415     PISSN: 00912700     EISSN: None     Source Type: Journal    
DOI: 10.1177/0091270004263045     Document Type: Conference Paper

References (44)

1. Ostrander LD, Francis T, Hayner NS, Kjeslberg MO, Epstein FH: The relationship of cardiovascular disease to hyperglycemia. Ann Intern Med 1965;62:1188-1197.
2. Kannel WB, McGee DL: Diabetes and cardiovascular disease: the Framingham study. JAMA 1979;241:2035-2038.
3. Fuller JH, Shipley MJ, Rose G, Jarrett RJ, Keen H: Coronary-heart-disease risk and impaired glucose tolerance: the Whitehall study. Lancet 1980;1:1373-1376.
4. Kleinman JC, Donahue RP, Harris MI, Finucane FF, Madans JH, Brock DB: Mortality among diabetics in a national sample. Am J Epidemiol 1988;128:389-401.
5. Rosengren A, Welin L, Tsipogianni A, Wilhelmsen L: Impact of cardiovascular risk factors on coronary heart disease and mortality among middle aged diabetic men: a general population study. Br Med J 1989;299:1127-1131.
6. Kannel WB, McGee DL: Diabetes and glucose tolerance as risk factors for cardiovascular disease: the Framingham study. Diabetes Care 1979;2:120-126.
7. Barrett-Connor E, Wingard DL: Sex differential in ischemic heart disease mortality in diabetics: a prospective population-based study. Am J Epidemiol 1983;118:489-496.
8. Miettinen H, Lehto S, Salomaa V, et al for the FINMONICA Myocardial Infarction Register Study Group: Impact of diabetes on mortality after the first myocardial infarction. Diabetes Care 1998;21:69-75.
9. Sprafka JM, Burke GL, Folsom AR, McGovern PG, Hahn LP: Trends in prevalence of diabetes mellitus in patients with myocardial infarction and effect of diabetes on survival: the Minnesota Heart Survey. Diabetes Care 1991;14:537-543.
10. Chun BY, Dobson AJ, Heller RF: The impact of diabetes on survival among patients with first myocardial infarction. Diabetes Care 1997;20:704-708.
11. Escobedo LG, Caspersen CJ: Risk factors for sudden coronary death in the United States. Epidemiology 1997;8:175-180.
12. Gu K, Cowie CC, Harris MI: Diabetes and decline in heart disease mortality in US adults. JAMA 1999;281:1291-1297.
13. Haffner SM, Lehto S, Ronnemaa T, Pyorala K, Laakso M: Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. N Engl J Med 1998;339:229-234.
14. Executive summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA 2001;285:2486-2497.
15. The Diabetes Control and Complications Trial Research Group: The effect of intensive diabetes treatment on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 1986;329:977-986.
16. UK Prospective Diabetes Study (UKPDS) Group: Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998;352:837-853.
17. UK Prospective Diabetes Study (UKPDS) Group: Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet 1998;1352(9131):854-865.
18. Nagi DK, Yudkin JS: Effects of metformin on insulin resistance, risk factors for cardiovascular disease, and plasminogen activator inhibitor in NIDDM subjects: a study of two ethnic groups. Diabetes Care 1993;16:621-629.
19. Turner RC, Holman R, Stratton I: Correspondence. The UK Prospective Diabetes Study. Lancet 1999;352:1934.
20. Stratton IM, Adler AI, Neil HA, Matthews DR, Manley SE, Cull CA, et al: Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. Br Med J 2000;321(7258):405-412.
21. Abraira C, Henderson WG, Colwell JA, et al: Response to intensive therapy steps and to glipizide dose in combination with insulin in type 2 diabetes: VA feasibility study on glycemic control and complications (VA CSDM). Diabetes Care 1998;21(4):574-579.
22. Duckworth WC, McCarren M, Abraira C: Glucose control and cardiovascular complications: the VADT trial. Diabetes Care 2001;24(5):942-945.
23. ADA clinical practice guidelines. Diabetes Care 2004;27:S15-S35.
24. Fagan TC, Deedwania PC: The cardiovascular dysmetabolic syndrome. Am J Med 1998;105(1A):77S-82S.
25. Mudaliar S, Henry RR: The oral hypoglycemic agents, in: Porte D, Sherwin R, Baron A (eds.), Ellenberg and Rifkin's Diabetes Mellitus. 6th ed. New York: McGraw-Hill, 2002;531-564.
26. Mudaliar S, Henry RR: New oral therapies for type 2 diabetes: the glitazones or insulin sensitizers. Annu Rev Med 2001;52:239-257.
27. Minamikawa J, Tanaka S, Yamauchi M, et al: Potent inhibitory effect of troglitazone on carotid arterial wall thickness in type 2 diabetes. J Clin Endocrinol Metab 1998;83:1818-1820.
28. Koshiyama H, Shimono D, Kuwamura N, Minamikawa J, Nakamura Y: Inhibitory effect of pioglitazone on carotid arterial wall thickness in type 2 diabetes. J Clin Endocrinol Metab 2001;86:3452-3456.
29. Mudaliar S, Edelman SV: Insulin therapy for patients with type 2 diabetes mellitus. Endo Metab Clin N Am 2001;30(4):935-982.
30. Malmberg K and the DIGAMI (Diabetes Mellitus, Insulin Glucose Infusion in Acute Myocardial Infarction) Study Group: Prospective randomized study of intensive insulin treatment on long-term survival after acute myocardial infarction in patients with diabetes mellitus. Br Med J 1997;314:1512-1515.
31. Malmberg K, Norhammar A, Wedel H, et al: Glycometabolic state at admission: important risk marker of mortality in conventionally treated patients with diabetes mellitus and acute myocardial infarction: long-term results from the Diabetes and Insulin-Glucose Infusion in Acute Myocardial Infarction (DIGAMI) study. Circulation 1999;99:2626-2632.
32. Colwell, Shechter M, Merz CN, Paul-Labrador MJ, Kaul S: Blood glucose and platelet-dependent thrombosis in patients with coronary artery disease. J Am Coll Cardiol 2000;35:300-307.
33. Colwell JA: Aspirin therapy in diabetes (technical review). Diabetes Care 1997;20:1767-1771.
34. Antiplatelet Trialists' Collaboration: Collaborative overview of randomized trials of antiplatelet therapy: prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. Br Med J 1994;308:81-106.
35. Hansson L, Zanchetti A, Carruthers SG, et al for the HOT Study Group: Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomized trial. Lancet 1998;351:1755-1762.
36. ETDRS Investigators: Aspirin effects on mortality and morbidity in patients with diabetes mellitus: Early Treatment in Diabetic Retinopathy Study report. JAMA 1992;288:1292-1300.
37. Harpaz D, Gottlieb S, Graff E, Boyko V, Kishon Y, Behar S: Effects of aspirin treatment on survival in non-insulin-dependent diabetic patients with coronary artery disease. Israeli Bezafibrate Infarction Prevention Study Group. Am J Med 1998;105(6):494-499.
38. Steering Committee of the Physicians' Health Study Research Group: Final report on the aspirin component of the ongoing Physicians' Health Study. N Engl J Med 1989;321:129-135.
39. Gordon JL: Overview: pharmacology of ticlopidine. Agents Actions Suppl 1984;15:108-115.
40. Herbert JM, Frechel D, Vallee E, et al: Clopidogrel, a novel antiplatelet and antithrombotic agent. Cardiovasc Drug Rev 1993;11:180-198.
41. 3H]-2-methylthio ADP to rat platelets: effect of clopidogrel and ticlopidine. J Pharmacol Exp Ther 1994;269:772-777.
42. CAPRIE Steering Committee: A randomised, blinded trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). Lancet 1996;348:1329-1339.
43. The Clopidogrel in Unstable Angina to Prevent Recurrent Events Trial Investigators: Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med 2001;345:494-502.
44. Gaede P, Vedel P, Larsen N, et al: Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes. N Engl J Med 2003;348:383-393.